ICER
ICER
  • ICER Analytics™
  • Donate
search
  • Who We Are
    • History & Impact
    • People
    • Independent Funding
    • Careers
    • Frequently Asked Questions (FAQs)
  • Our Approach
    • Methods & Process
    • Policies
  • Engage with ICER
    • Patients
    • Clinicians
    • Manufacturers
    • Prospective Employees
    • Committees & Boards
  • News & Insights
    • Press Releases
    • Commentaries
    • Journal Articles
    • Weekly View
  • Explore Our Research
    • Assessments
    • Policy Papers
    • ICER Calendar
    • ICER ANALYTICS™
Explore Our Research / Assessments / Multiple Sclerosis: SPMS

Multiple Sclerosis: SPMS

An assessment of tolebrutinib

Public Meeting
June 2025

Assessment Status

Open

Public Comments

Closed

Upcoming Milestone

Final Evidence Report and Meeting SummaryView

  • Overview
  • Full Timeline & Materials
  • Related Assessments & Articles

Interventions of Interest

  • tolebrutinib (Sanofi)

For questions please contact [email protected].

View the Key Stakeholder List.

Main Review
June 13, 2025

CTAF

The CTAF’s 2025 public meeting on tolebrutinib:

  • Evidence Presentation
  • Public Comments
  • Voting Questions
  • Policy Roundtable

 

Multiple Sclerosis: SPMS Meeting Agenda

Related Assessments & Policy Papers.

Woman_in_passing

Multiple Sclerosis: CIS, RRMS, and SPMS

 Jan 2023

Multiple Sclerosis: RRMS and PPMS

 Feb 2017

Multiple Sclerosis: SPMS

 May 2019
11/19/2024

Draft Scoping Document

Download PDF

11/19/2024 - 12/10/2024

Public Comments on Draft Scoping Document

Download PDF

12/18/2024

Revised Scoping Document

Download PDF

01/08/2025

Research Protocol

Please find the research protocol here: https://osf.io/ju4vc/

02/24/2025

Model Analysis Plan

Please find the model analysis plan here: https://osf.io/r5vy2 

04/15/2025

Draft Evidence Report

Having trouble viewing the report? Click here. 

 

Download PDF

Draft Voting Questions

04/15/2025 - 05/13/2025

Public Comments on Draft Evidence Report

Download PDF

05/29/2025

Evidence Report

Download PDF

Revised Voting Questions

Response to Public Comments

06/13/2025

Evidence Presentation

Download PDF

07/15/2025

Final Evidence Report and Meeting Summary

Related Assessments & Policy Papers

Multiple Sclerosis: CIS, RRMS, and SPMS

 Jan 2023 New England CEPAC

Multiple Sclerosis: RRMS and PPMS

 Feb 2017

Multiple Sclerosis: SPMS

 May 2019

Related Press Releases

Institute for Clinical and Economic Review Publishes Evidence Report on Treatment for Secondary Progressive Multiple Sclerosis

There are significant uncertainties regarding long term efficacy of tolebrutinib; ICER estimates that treatment would achieve common thresholds of cost-effectiveness if priced between $3,250 and $5,900 per year.

Read More 05/29/2025

Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatment for Secondary Progressive Multiple Sclerosis

Public comment period now open until May 13, 2025; Requests to make oral comment during public meeting also being accepted.

Read More 04/15/2025

Institute for Clinical and Economic Review to Assess Treatment for Secondary Progressive Multiple Sclerosis

Report will be subject of CTAF meeting in June 2025; Draft Scoping Document open to public comment until December 10, 2024.

Read More 11/19/2024
Go to Press Releases

Back to Top
  • Contact
  • Careers
  • Find a Report
  • Donate
  • ICER ANALYTICS™ LOGIN

OUR NEWSLETTER.

A weekly digest of the top news
on ICER and US drug pricing. Sign Up


CONTACT US

+1 (617) 528-4013

Email: [email protected]

Media Inquiries: [email protected]

ICER
© ICER, 2025
  • Terms and Conditions
  • Privacy Policy
  • Accessibility Statement
Linkedin
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT